US FDA approves Revolution Medicines' pancreatic cancer drug
The once-daily pill improved median overall survival to 13.2 months in a 500-patient trial, compared with 6.7 months for chemotherapy.
- On Aug 26, The FDA approved Rasonque, a new drug from Revolution Medicines for adults with advanced pancreatic cancer who have received prior treatment.
- Designed as a once-daily pill, Rasonque functions by blocking several forms of the RAS protein, which drives tumor growth in pancreatic cancer.
- Data from a study of 500 adults showed the drug improved median overall survival to 13.2 months, compared with 6.7 months on standard chemotherapy.
- Andrew Ko, a medical oncologist at the University of California, San Francisco, called it "the biggest development we've had in pancreas cancer in decades."
- Revolution did not immediately respond to a request from Reuters for comment on the drug's pricing and availability following the regulatory clearance.
67 Articles
67 Articles
The Pill That Just Cut the Deadliest Cancer's Death Risk by 60% Finally Got FDA's Yes
A once-daily cancer pill that cut the risk of death by 60 per cent in patients with advanced pancreatic cancer has been approved in the US, nearly doubling median survival compared with standard chemotherapy. The FDA cleared Rasonque, also known as Daraxonrasib, on Wednesday for adults with previously treated metastatic pancreatic ductal adenocarcinoma, offering a new option for people facing one of the world's deadliest cancers. In the pivotal …
Revolution Medicines gets FDA approval for targeted pancreatic cancer drug
The drug, branded as Rasonque and also known as daraxonrasib, is a once-daily pill designed to block several forms of the RAS protein, which helps drive tumor growth in many pancreatic cancers.
The medicine passed Phase II clinical trials with amazing results: doubled the life span of patients with metastatic pancreatic cancer and can now be marketed in the United States
Coverage Details
Bias Distribution
- 72% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
